FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Nubratori Dexonto 0 Recall

Dexonto 0

Nubratori, Inc · Torrance, CA

Risk level
Class II
Reported by FDA
May 7, 2025
Recall ID
D-0392-2025
Check your lot numberHow we source this data

Summary

Nubratori recalled Dexonto 0 starting Apr 15, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0392-2025 on May 7, 2025. Reason: Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025. Status: Ongoing.

Why it was recalled

Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.

Product description

Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 mg/mL), Rx Only, 12 - 5 mL Single Dose Units per box, Preservative Free, For Iontophoresis Use Only, Non-Sterile Product, Not for Injection, NUBRATORI RX, 381 Van Ness Ave# 1507, CA 90501, NDC 71300-6564-1 (box), 71300-6564-3 (vial).

Lot numbers, UPCs & expiration codes

Lot #: C04292401X1, BUD: 12/25/2025 (box).

Where it was sold

PA and CA.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0392-2025
Classification
Class II
Status
Ongoing
Recall initiated
Apr 15, 2025
FDA report date
May 7, 2025
Quantity
20 boxes
Recall type
Voluntary: Firm initiated
Recalling firm
Nubratori, Inc

Original FDA data

Every field from FDA enforcement report D-0392-2025, exactly as published.

Show all FDA fields
City
Torrance
State
CA
Status
Ongoing
Country
United States
Event ID
96699
Address
381 Van Ness Ave Ste 1507
Code information
Lot #: C04292401X1, BUD: 12/25/2025 (box).
Postal code
90501-7220
Report date
May 7, 2025
Product type
Drugs
Recall number
D-0392-2025
Classification
Class II
Recalling firm
Nubratori, Inc
Product quantity
20 boxes
Reason for recall
Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 mg/mL), Rx Only, 12 - 5 mL Single Dose Units per box, Preservative Free, For Iontophoresis Use Only, Non-Sterile Product, Not for Injection, NUBRATORI RX, 381 Van Ness Ave# 1507, CA 90501, NDC 71300-6564-1 (box), 71300-6564-3 (vial).
Distribution pattern
PA and CA.
Recall initiation date
Apr 15, 2025
Initial firm notification
Letter
Center classification date
Apr 28, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0392-2025, published May 7, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls